Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adverse events in nuclear medicine

Literature DB >> 22310855

Adverse events in nuclear medicine - cause for concern?

B Hesse, N Vinberg, A K Berthelsen, J R Ballinger.

Abstract

Mesh：

Substances：

Year: 2012 PMID： 22310855 DOI： 10.1007/s00259-012-2071-6

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

16 in total

1. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000.

Authors: S E Hesslewood
Journal: Eur J Nucl Med Mol Imaging Date: 2002-04-12 Impact factor: 9.236

2. [The 27th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 30th survey in 2004)].

Authors: Kiyoko Kusakabe; Terue Okamura; Kanji Kasagi; Akio Komatani; Yukimitsu Sato; Hiroshi Matsuda; Hirotaka Maruno
Journal: Kaku Igaku Date: 2006-02

3. Frequency of adverse reactions to radiopharmaceuticals in Europe.

Authors: S R Hesslewood; D H Keeling
Journal: Eur J Nucl Med Date: 1997-09

4. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Authors: Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

Review 5. Neuroendocrine tumors. Peptide receptor radionuclide therapy.

Authors: Flavio Forrer; Roelf Valkema; Dik J Kwekkeboom; Marion de Jong; Eric P Krenning
Journal: Best Pract Res Clin Endocrinol Metab Date: 2007-03 Impact factor: 4.690

6. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Authors: Thomas E Witzig; Christine A White; Leo I Gordon; Gregory A Wiseman; Christos Emmanouilides; James L Murray; John Lister; Pratik S Multani
Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544

7. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Authors: G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette
Journal: Eur Urol Date: 2003-11 Impact factor: 20.096

Adverse events in nuclear medicine - cause for concern?

1. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000.

2. [The 27th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 30th survey in 2004)].

3. Frequency of adverse reactions to radiopharmaceuticals in Europe.

4. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Review 5. Neuroendocrine tumors. Peptide receptor radionuclide therapy.

6. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

7. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Review 8. Anaphylaxis: Recent advances in assessment and treatment.

9. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.

Review 10. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

1. Further considerations on adverse reactions to radiopharmaceuticals.

2. Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Review 3. Prospective of ⁶⁸Ga-radiopharmaceutical development.

4. Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration.